Loading...
Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?
Evans, D Gareth R Howell, Sacha J Howell, Anthony
Evans, D Gareth R
Howell, Sacha J
Howell, Anthony
Citations
Altmetric:
Abstract
Description
Date
2019
Publisher
Collections
Files
Keywords
Type
Article
Citation
Evans DG, Howell SJ, Howell A. Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy? Fam Cancer. 2019 Aug 23.